IntelGenx Technologies Corp. said March 27 that it is no longer looking to raise $10 million to fund the acquisition of a pharmaceutical consulting firm.
The company canceled its placement due to market conditions. The Canadian drug delivery company's acquisition of LaboVal Inc. was dependent on the financing.